Biologics Engineering - Cell Therapy & Engineering Intern jobs in United States
cer-icon
Apply on Employer Site
company-logo

Alexion Pharmaceuticals, Inc. · 14 hours ago

Biologics Engineering - Cell Therapy & Engineering Intern

positionGaithersburg, Maryland, United States of America
timeInternship
remoteOnsite
seniorityIntern
money$41.50/hr - $48/hr

Alexion Pharmaceuticals, Inc. is seeking Master's and PhD level students for a 12-week internship in Biologics Engineering focused on Cell Therapy. The role involves recommending protein targets for CAR-T therapy, generating necessary reagents, running assays, and making feasibility recommendations based on data.

BiotechnologyHealth CareMedicalTherapeutics
check
Comp. & BenefitsbadNo H1Bnote

Responsibilities

Use literature to recommend candidate protein targets to test in CAR-T therapy form
Generate reagents required to make CAR-T therapy including lentivirus and immune cell culture
Run assays culturing their candidate CAR-T therapies with target cells and using flow cytometry to determine therapy efficacy
Make recommendations based on their data on the feasibility of the candidate therapy designs they tested

Qualification

Wet lab skillsFlow cytometryImmune cell cultureLiterature searchData analysis

Required

Master's and PhD level students majoring in Biomedical Engineering, Biology, Immunology or a related discipline. Candidates must have an expected graduation date after August 2026
Wet lab skills such as pipetting and aseptic technique for cell culture are required
Ability to report onsite to Gaithersburg, MD 5 days per week; this position may require occasional onsite weekend hours
US Work Authorization is required at time of application
This role will not be providing OPT support

Preferred

Experience with flow cytometry is preferred
Literature search and data analysis using Excel and basic stats (e.g. Prism) are a plus
Experience with immune cell culture is a plus

Company

Alexion Pharmaceuticals, Inc.

twittertwittertwitter
Glassdoor3.9
company-logo
Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community.
dateFounded in 1992
location
Boston, Massachusetts, USA
people-size1001-5000 employees
web-link
https://alexion.com

Funding

Current Stage
Public Company
Total Funding
$5.8M
2020-12-12Acquired
1999-02-12Post Ipo Equity· $5.8M
1996-02-29IPO

Leadership Team

leader-logo
Frederic Chereau
SVP, Strategy and Business Development
linkedin
leader-logo
Imran Shakur
Director, IRT and Technology Lead
linkedin

Recent News

BioWorld Financial Watch
Alexion Pharmaceuticals discloses C1S inhibitors
2026-01-17
bloomberglaw.com
AstraZeneca Unit Gets Partial Win in Soliris Drug Monopoly Case
2025-12-20
Business Wire
Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline and Competitive Intelligence Report 2025 - ResearchAndMarkets.com
2025-12-01
Company data provided by crunchbase